Cer 116:45414548, 2010 26. Dang NH, Pro B, Hagemeister FB, et al: Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136: 439-447, 2007 26a. Enblad G, Hagberg H, Erlanson M, et al: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or TLR3 Agonist Storage & Stability chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920-2924, 2004 27. Coiffier B, Pro B, Prince HM, et al: Outcomes from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma following prior systemic therapy. J Clin Oncol 30:631-636, 2012 28. O’Connor OA, Pro B, Pinter-Brown L, et al: Pralatrexate in individuals with relapsed or refractory peripheral T-cell lymphoma: Results in the pivotal PROPEL study. J Clin Oncol 29:1182-1189, 2011 28a. Coiffier B, Pro B, Prince M, et al: Romidepsin induces durable responses in sufferers with peripheral T-cell lymphoma: GPI-06-0002 study update. 54th Annual Meeting with the American Society of Hematology, Atlanta, GA, December 8-11, 2012 (abstr 3641) 29. Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in individuals with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 30:2190-2196, 2012 30. Arkenau HT, Chong G, Cunningham D, et al: Gemcitabine, cisplatin and methylprednisolone for the therapy of individuals with peripheral T-cell lymphoma: The Royal Marsden Hospital encounter. Haematologica 92:271-272, 2007 31. Crump M, Shepherd L, Lin B: A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab upkeep therapy versus observation for remedy of aggressive B-cell and T-cell non-Hodgkin’s lymphoma. Clin Lymphoma 6:56-60, 2005 32. Horwitz S MC, Kewalramani T, et al: Secondline therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: Minimal benefit when analyzed by intent to treat. Blood 106, 2005 (abstr 2679) 33. Damaj G, Gressin R, Bouabdallah K, et al: Results from a potential, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial. J Clin Oncol 31:104-110,NK2 Agonist review JOURNAL OF CLINICAL ONCOLOGY
The potato enzyme FHT (fatty -hydroxyacid/fatty alcohol hydroxycinnamoyl transferase) plus the respective Arabidopsis orthologue ASFT/RWP1/AtHHT (At5g41040) have previously been characterized both in vitro and in planta (Gou et al., 2009; Molina et al., 2009; Serra et al., 2010b). Categorized as acyltransferases on the BAHD household capable of undertaking the in vitro catalytic transfer of ferulic acid from feruloyl-CoA to -hydroxyfatty acids and fatty alcohols, each enzyme orthologues are responsible for supplying monomers to suberin (reviewed by Liu, 2010; Serra et al., 2010a). Suberin consists of a complex cell wall polymer that is employed by land plants to regulate the apoplastic transport of water (see, among others, Bernards, 2002; Ranathunge et al., 2011; Beisson et al., 2012), becoming composed of an aliphatic domain cross-linked having a lignin-like aromatic domain that may be fixed towards the key cell wall. The aliphatic domain is created up of a glycerol-based fatty acid-derived polyester which types a matrix in which soluble lipids or waxes are embedded.The Author [2013]. Published by Oxford University Pre.
